The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans

Journal of Clinical Investigation

Volumn 122, Issue 6, 2012, Pages 2176-2194

  Benhamed, Fadila ^a,b,c   Denechaud, Pierre Damien ^a,b,c   Lemoine, Maud ^d,e,f   Robichon, Céline ^a,b,c   Moldes, Marthe ^a,b,c   Bertrand Michel, Justine ^g   Ratziu, Vlad ^f   Serfaty, Lawrence ^d,e,f   Housset, Chantal ^d,e   Capeau, Jacqueline ^d,e   Girard, Jean ^a,b,c   Guillou, Hervé ^h   Postic, Catherine ^a,b,c  

^a INSTITUT COCHIN   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g INSERM   (France)

^h TOXALIM RESEARCH CENTRE IN FOOD TOXICOLOGY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DESATURASE 1; FATTY ACID; INSULIN; MONOUNSATURATED FATTY ACID; PROTEIN KINASE B; SATURATED FATTY ACID; SHORT HAIRPIN RNA; STEAROYL COENZYME A; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET; ENZYME ACTIVITY; ESTERIFICATION; FATTY LIVER; FEMALE; GENE OVEREXPRESSION; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIPID METABOLISM; LIPOGENESIS; LIVER BIOPSY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STEATOSIS;

ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; FATTY ACIDS, MONOUNSATURATED; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; LIPOGENESIS; LIVER; MALE; METABOLIC SYNDROME X; MICE; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; STEAROYL-COA DESATURASE; TRANSCRIPTION FACTORS;

EID: 84861809881     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI41636     Document Type: Article

References (92)

1. Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol. 2010;26(3):202-208.
2. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011; 33(5):525-540.
3. Abdelmalek MF, Diehl AM. Nonalcoholic Fatty liver disease as a complication of insulin resistance. Med Clin North Am. 2007;91(6):1125-1149. (Pubitemid 47625434)
4. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2(12):1048-1058. (Pubitemid 40037633)
5. Yamaguchi K, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45(6):1366-1374. (Pubitemid 46918320)
6. Listenberger LL, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A. 2003;100(6):3077-3082. (Pubitemid 36356542)
7. Neuschwander-Tetri BA. Nontriglyceride hepatic lipotoxicity: the new paradigm for the pathogenesis of NASH. Curr Gastroenterol Rep. 2010;12(1):49-56.
8. Kumashiro N, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A. 2011;108(39):16381- 16385.
9. Monetti M, et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab. 2007;6(1):69-78. (Pubitemid 46995777)
10. Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol. 2004;40(1):47-51. (Pubitemid 38064712)
11. Buettner R, Ottinger I, Scholmerich J, Bollheimer LC. Preserved direct hepatic insulin action in rats with diet-induced hepatic steatosis. Am J Physiol Endocrinol Metab. 2004;286(5):E828-E833. (Pubitemid 38506954)
12. Stefan N, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168(15):1609-1616.
13. Lodhi IJ, Wei X, Semenkovich CF. Lipoexpediency: de novo lipogenesis as a metabolic signal transmitter. Trends Endocrinol Metab. 2011;22(1):1-8.
14. Carobbio S, Rodriguez-Cuenca S, Vidal-Puig A. Origins of metabolic complications in obesity: ectopic fat accumulation. The importance of the qualitative aspect of lipotoxicity. Curr Opin Clin Nutr Metab Care. 2011;14(6):520-526.
15. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest. 2008;118(3):829-838. (Pubitemid 351364588)
16. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343-1351. (Pubitemid 40629054)
17. Dentin R, et al. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J Biol Chem. 2004;279(19):20314-20326. (Pubitemid 38623477)
18. Ishii S, Iizuka K, Miller BC, Uyeda K. Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc Natl Acad Sci U S A. 2004;101(44):15597-15602. (Pubitemid 39473533)
19. Ma L, Tsatsos NG, Towle HC. Direct role of ChREBP.Mlx in regulating hepatic glucose-responsive genes. J Biol Chem. 2005;280(12):12019-12027. (Pubitemid 40418520)
20. Guinez C, et al. O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver. Diabetes. 2011;60(5):1399-1413.
21. Bricambert J, Miranda J, Benhamed F, Girard J, Postic C, Dentin R. Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice. J Clin Invest. 2010;120(12):4316-4331.
22. Kabashima T, Kawaguchi T, Wadzinski BE, Uyeda K. Xylulose 5-phosphate mediates glucose-induced lipogenesis by xylulose 5-phosphate-activated protein phosphatase in rat liver. Proc Natl Acad Sci U S A. 2003;100(9):5107-5112. (Pubitemid 36542666)
23. Denechaud PD, et al. ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver. J Clin Invest. 2008;118(3):956-964.
24. Dentin R, et al. Glucose 6-phosphate, rather than xylulose 5-phosphate, is required for the activation of ChREBP in response to glucose in liver. J Hepatol. 2012;56(1):199-209.
25. Iizuka K, Bruick RK, Liang G, Horton JD, Uyeda K. Deficiency of carbohydrate response elementbinding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci U S A. 2004; 101(19):7281-7286. (Pubitemid 38638024)
26. Iizuka K, Miller B, Uyeda K. Deficiency of carbohydrate- activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob/ob) mice. Am J Physiol Endocrinol Metab. 2006;291(2):E358-E364. (Pubitemid 44043073)
27. Dentin R, et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes. 2006;55(8):2159-2170. (Pubitemid 44743612)
28. Foretz M, Guichard C, Ferré P, Foufelle F. Sterol regulatoy element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc Natl Acad Sci U S A. 1999;96(22):12737-12742. (Pubitemid 29513572)
29. Virtue S, Vidal-Puig A. It's not how fat you are, it's what you do with it that counts. PLoS Biol. 2008; 6(9):e237.
30. Holland WL, Knotts TA, Chavez JA, Wang LP, Hoehn KL, Summers SA. Lipid mediators of insulin resistance. Nutr Rev. 2007;65(6 pt 2):S39-S46.
31. Samuel VT, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279(31):32345-32353. (Pubitemid 39014687)
32. Samuel VT, et al. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest. 2007; 117(3):739-745. (Pubitemid 46348532)
33. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5(6):426-437. (Pubitemid 46825495)
34. Iizuka K, Takeda J, Horikawa Y. Glucose induces FGF21 mRNA expression through ChREBP activation in rat hepatocytes. FEBS Lett. 2009; 583(17):2882-2886.
35. Flowers MT, Ntambi JM. Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism. Curr Opin Lipidol. 2008;19(3):248-256. (Pubitemid 351653562)
36. Paton CM, Ntambi JM. Loss of stearoyl-CoA desaturase activity leads to free cholesterol synthesis through increased Xbp-1 splicing. Am J Physiol Endocrinol Metab. 2010;299(6):E1066-E1075.
37. Sampath H, Ntambi JM. The role of stearoyl-CoA desaturase in obesity, insulin resistance, and inflammation. Ann N Y Acad Sci. 2011;1243(1):47-53.
38. Miyazaki M, et al. Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. Cell Metab. 2007; 6(6):484-496. (Pubitemid 350163054)
39. Ariyama H, Kono N, Matsuda S, Inoue T, Arai H. Decrease in membrane phospholipid unsaturation induces unfolded protein response. J Biol Chem. 2010; 285(29):22027-22035.
40. Thorn K, Hovsepyan M, Bergsten P. Reduced levels of SCD1 accentuate palmitate-induced stress in insulin-producing beta-cells. Lipids Health Dis. 2010; 9:108.
41. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007;8(7):519-529. (Pubitemid 46985379)
42. Flamment M, Kammoun HL, Hainault I, Ferre P, Foufelle F. Endoplasmic reticulum stress: a new actor in the development of hepatic steatosis. Curr Opin Lipidol. 2010;21(3):239-246.
43. Louvet A, et al. Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology. 2011; 54(4):1217-1226.
44. Puigserver P, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature. 2003;423(6939):550-555. (Pubitemid 36648580)
45. Dentin R, et al. Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature. 2007; 449(7160):366-369. (Pubitemid 47443476)
46. Zhang EE, et al. Cryptochrome mediates circadian regulation of cAMP signaling and hepatic gluconeogenesis. Nat Med. 2010;16(10):1152-1156.
47. Kharitonenkov A, Shanafelt AB. Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. BioDrugs. 2008;22(1):37-44. (Pubitemid 351158533)
48. Ratziu V, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo- controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008;135(1):100-110. (Pubitemid 351916703)
49. Marchesini G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50(8):1844-1850. (Pubitemid 33641605)
50. Anstee QM, Goldin RD. Mouse models in nonalcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol. 2006;87(1):1-16.
51. Tsatsos NG, Towle HC. Glucose activation of ChREBP in hepatocytes occurs via a two-step mechanism. Biochem Biophys Res Commun. 2006; 340(2):449-456. (Pubitemid 43021769)
52. Guha P, Aneja KK, Shilpi RY, Haldar D. Transcriptional regulation of mitochondrial glycerophosphate acyltransferase is mediated by distal promoter via ChREBP and SREBP-1. Arch Biochem Biophys. 2009;490(2):85-95.
53. Jeong YS, et al. Integrated expression profiling and genome-wide analysis of ChREBP targets reveals the dual role for ChREBP in glucose-regulated gene expression. PLoS One. 2011;6(7):e22544.
54. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52(2):774-788.
55. Farese RV Jr, Walther TC. Lipid droplets finally get a little R-E-S-P-E-C-T. Cell. 2009;139(5):855-860.
56. Koliwad SK, et al. DGAT1-dependent triacylglycerol storage by macrophages protects mice from diet-induced insulin resistance and inflammation. J Clin Invest. 2010;120(3):756-767.
57. Son NH, et al. PPARgamma-induced cardiolipotoxicity in mice is ameliorated by PPARalpha deficiency despite increases in fatty acid oxidation. J Clin Invest. 2010;120(10):3443-3454.
58. Timmers S, et al. Prevention of high-fat diet-induced muscular lipid accumulation in rats by alpha lipoic acid is not mediated by AMPK activation. J Lipid Res. 2010;51(2):352-359.
59. Guillou H, Zadravec D, Martin PG, Jacobsson A. The key roles of elongases and desaturases in mammalian fatty acid metabolism: Insights from transgenic mice. Prog Lipid Res. 2010;49(2):186-199.
60. Moon YA, Hammer RE, Horton JD. Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice. J Lipid Res. 2009;50(3):412-423.
61. Akazawa Y, et al. Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol. 2010;52(4):586-593.
62. Cazanave SC, Elmi NA, Akazawa Y, Bronk SF, Mott JL, Gores GJ. CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. Am J Physiol Gastrointest Liver Physiol. 2010;299(1):G236-G243.
63. Miyazaki M, et al. Stearoyl-CoA desaturase 1 gene expression is necessary for fructose-mediated induction of lipogenic gene expression by sterol regulatory element-binding protein-1c-dependent and -independent mechanisms. J Biol Chem. 2004; 279(24):25164-25171. (Pubitemid 38756766)
64. Flowers JB, et al. Loss of stearoyl-CoA desaturase-1 improves insulin sensitivity in lean mice but worsens diabetes in leptin-deficient obese mice. Diabetes. 2007; 56(5):1228-1239. (Pubitemid 46715602)
65. Li ZZ, Berk M, McIntyre TM, Feldstein AE. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem. 2009;284(9):5637-5644.
66. Chen C, et al. Metabolomics reveals that hepatic stearoyl- CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. Cell Metab. 2008; 7(2):135-147. (Pubitemid 351168558)
67. Tardif N, et al. Oleate-enriched diet improves insulin sensitivity and restores muscle protein synthesis in old rats. Clin Nutr. 2011;30(6):799-806.
68. Minehira K, et al. Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J Lipid Res. 2008; 49(9):2038-2044.
69. Chen KS, Heydrick SJ, Brown ML, Friel JC, Ruderman NB. Insulin increases a biochemically distinct pool of diacylglycerol in the rat soleus muscle. Am J Physiol. 1994;266(3 pt 1):E479-E485.
70. Nagle CA, Klett EL, Coleman RA. Hepatic triacylglycerol accumulation and insulin resistance. J Lipid Res. 2009;50 suppl:S74-S79.
71. Wu C, et al. Enhancing hepatic glycolysis reduces obesity: differential effects on lipogenesis depend on site of glycolytic modulation. Cell Metab. 2005; 2(2):131-140.
72. de Luis O, Valero MC, Jurado LA. WBSCR14, a putative transcription factor gene deleted in Williams- Beuren syndrome: complete characterisation of the human gene and the mouse ortholog. Eur J Hum Genet. 2000;8(3):215-222. (Pubitemid 30189866)
73. Noriega LG, et al. CREB and ChREBP oppositely regulate SIRT1 expression in response to energy availability. EMBO Rep. 2011;12(10):1069-1076.
74. Rodgers JT, Puigserver P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc Natl Acad Sci U S A. 2007; 104(31):12861-12866. (Pubitemid 47255245)
75. Liu Y, et al. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature. 2008;456(7219):269-273.
76. Canto C, Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol. 2009;20(2):98-105.
77. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature. 2005;434(7029):113-118. (Pubitemid 40349395)
78. Kohjima M, et al. Re-evaluation of fatty acid metabolism- related gene expression in nonalcoholic fatty liver disease. Int J Mol Med. 2007;20(3):351-358.
79. Hurtado Del Pozo C, et al. ChREBP expression in the liver, adipose tissue and differentiated preadipocytes in human obesity. Biochim Biophys Acta. 2011;1811(12):1194-1200.
80. Kantartzis K, et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes. 2009;58(11):2616-2623.
81. Semple RK, et al. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest. 2009;119(2):315-322.
82. Dentin R, et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes. 2006;55(8):2159-2170. (Pubitemid 44743612)
83. Green H, Kehinde O. An established preadipose cell line and its differentiation in culture. II. Factors affecting the adipose conversion. Cell. 1975; 5(1):19-27.
84. Carre N, Cauzac M, Girard J, Burnol AF. Dual effect of the adapter growth factor receptor-bound protein 14 (grb14) on insulin action in primary hepatocytes. Endocrinology. 2008;149(6):3109-3117. (Pubitemid 351724508)
85. Barrans A, et al. Hepatic lipase induces the formation of pre-beta 1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases. J Biol Chem. 1994;269(15):11572-11577.
86. Vieu C, et al. Coupled assay of sphingomyelin and ceramide molecular species by gas liquid chromatography. J Lipid Res. 2002;43(3):510-522. (Pubitemid 34252281)
87. El Hadri K, et al. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. J Biol Chem. 2004; 279(15):15130-15141. (Pubitemid 38618908)
88. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4):402-408. (Pubitemid 34164012)
89. Dentin R, Hedrick S, Xie J, Yates J 3rd, Montminy M. Hepatic glucose sensing via the CREB coactivator CRTC2. Science. 2008;319(5868):1402-1405. (Pubitemid 351354877)
90. Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med. 2002;19(7):527-534. (Pubitemid 35300672)
91. Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-1321. (Pubitemid 40770284)
92. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999; 94(9):2467-2474. (Pubitemid 29420675)